Biocytogen

Biocytogen (Stock Code: 02315.HK) is an international biotechnology company driven by innovative technology for new drug R&D, committed to becoming a global source of new drugs, with the mission of focusing on technological innovation, continuous production of new drugs, and safeguarding human health. Based on the fully human antibody RenMice® platform (RenMab®, RenLite®, and RenNano® mice) independently developed by Biocytogen with completely independent intellectual property rights, the company organically integrates monoclonal antibody, bispecific antibody, and nanobody development technology platforms, in vivo efficacy screening platforms in animals, and strong clinical development capabilities, forming a unique new drug R&D capability covering the entire process of drug development. Biocytogen is conducting large-scale drug development for more than 1000 potentially druggable targets (the "1000 Antibodies, 1000 TargetsTM" plan). With the implementation of the plan, Biocytogen has signed 28 drug collaboration and development agreements and has reached RenMice® platform licensing collaborations with 16 companies, including multiple MNCs. The company has now established a pipeline of 12 core drug products, of which 2 products are in Phase II of international multi-center (MRCT) clinical trials and 2 are in Phase I clinical trials. In the future, Biocytogen will continue to collaborate with global partners to continuously produce numerous antibody drugs and better benefit patients. Biocytogen is headquartered in Beijing, with branches in Haimen, Jiangsu, Shanghai, Boston, USA, and Heidelberg, Germany, among other locations.